Gene · 5696
Papers2,476
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,476
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity. | Int J Mol Sci | 2023 | 37108368 | PubTator, text mining | PubMed |
| HMGN1 enhances CRISPR-directed dual-function A-to-G and C-to-G base editing. | Nat Commun | 2023 | 37105976 | PubTator, text mining | PubMed |
| Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment. | Mol Oncol | 2023 | 37097039 | PubTator, text mining | PubMed |
| Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity. | Front Immunol | 2023 | 37090711 | PubTator, text mining | PubMed |
| Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS). | Pediatr Rheumatol Online J | 2023 | 37087470 | PubTator, text mining | PubMed |
| Immunogenic cell death in cancer immunotherapy. | BMB Rep | 2023 | 37081756 | PubTator, text mining | PubMed |
| Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. | Oncogenesis | 2023 | 37080999 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing reveals transcriptional profiles of monocytes in HBV-infected pregnant women during mid-pregnancy. | J Cell Mol Med | 2023 | 37078407 | PubTator, text mining | PubMed |
| Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications. | Biomark Res | 2023 | 37069649 | PubTator, text mining | PubMed |
| Development and validation of a novel M1 macrophage-related gene prognostic signature for lung cancer. | J Thorac Dis | 2023 | 37065568 | PubTator, text mining | PubMed |
| Case report: Schnitzler-like syndrome without monoclonal gammopathy. | Front Immunol | 2023 | 37063861 | PubTator, text mining | PubMed |
| Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction. | Front Immunol | 2023 | 37063830 | PubTator, text mining | PubMed |
| Omics are Getting Us Closer to Understanding IgA Nephropathy. | Arch Immunol Ther Exp (Warsz) | 2023 | 37060455 | PubTator, text mining | PubMed |
| Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. | J Clin Med | 2023 | 37048814 | PubTator, text mining | PubMed |
| Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway. | Int J Mol Sci | 2023 | 37047709 | PubTator, text mining | PubMed |
| MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. | Cell Rep Med | 2023 | 37044092 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma. | Sci Adv | 2023 | 37043580 | PubTator, text mining | PubMed |
| Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. | Nat Commun | 2023 | 37041154 | PubTator, text mining | PubMed |
| Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. | Nat Cancer | 2023 | 37038005 | PubTator, text mining | PubMed |
| Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials. | Front Immunol | 2023 | 37033930 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5696/papers?page=13